Showing 1 to 2 of 2 results


Oral Medication Shows Significant Weight Loss in Obesity Treatment
A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.
Oral Medication Shows Significant Weight Loss in Obesity Treatment
A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.
Progress
44% Bias Score

Pregabalin Linked to Increased Heart Failure Risk
A new study revealed a significantly increased risk of heart failure among pregabalin users, prompting doctors to reassess its prescription, especially in older patients with pre-existing heart conditions.

Pregabalin Linked to Increased Heart Failure Risk
A new study revealed a significantly increased risk of heart failure among pregabalin users, prompting doctors to reassess its prescription, especially in older patients with pre-existing heart conditions.
Progress
36% Bias Score
Showing 1 to 2 of 2 results